Phase II study of the novel antifolate agent pralatrexate in combination with the histone deacetylase inhibitor romidepsin for the treatment of patients with mature T-cell lymphoma.
Chemotherapeutic approaches
T-cell lymphoma
antifolate
clinical results
epigenetics
lymphoma and Hodgkin disease
Journal
Leukemia & lymphoma
ISSN: 1029-2403
Titre abrégé: Leuk Lymphoma
Pays: United States
ID NLM: 9007422
Informations de publication
Date de publication:
22 Mar 2024
22 Mar 2024
Historique:
medline:
22
3
2024
pubmed:
22
3
2024
entrez:
22
3
2024
Statut:
aheadofprint
Résumé
Previously, we conducted a Phase I study of the combination of pralatrexate and romidepsin in patients with relapsed/refractory (R/R) lymphomas and subsequently conducted a multicenter Phase II study in patients with untreated or R/R mature T cell lymphomas (MTCL). Patients received pralatrexate 25 mg/m
Identifiants
pubmed: 38517235
doi: 10.1080/10428194.2024.2329996
doi:
Banques de données
ClinicalTrials.gov
['NCT01947140']
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM